Welcome to our dedicated page for Ocugen SEC filings (Ticker: OCGN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Ocugen, Inc. (NASDAQ: OCGN) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. These documents are central for understanding Ocugen’s development plans in gene therapies for blindness diseases, its financial condition, and key corporate actions.
Ocugen uses Form 8‑K current reports to announce material events, including exclusive licensing agreements, registered direct offerings of common stock and warrants, litigation developments, and Nasdaq listing compliance updates. For example, recent 8‑K filings describe an exclusive license agreement with Kwangdong Pharmaceutical Co., Ltd. for OCU400 in the Republic of Korea, a securities purchase agreement for a registered direct offering, and court decisions related to a securities class action lawsuit.
Periodic reports such as Form 10‑Q and Form 10‑K (when available) provide more comprehensive information on Ocugen’s financial results, operating expenses, and risk factors. In a recent earnings-related press release furnished on Form 8‑K, the company detailed revenue from collaborative arrangements, research and development expenses, general and administrative expenses, and net loss figures, along with commentary on cash runway and financing plans.
Investors can also review filings that discuss executive compensation and equity awards, such as performance restricted stock units granted to senior leadership, and agreements related to licensing, supply, and regional commercialization of products like OCU400. These filings help clarify how management is incentivized and how Ocugen structures partnerships around its modifier gene therapy platform.
On Stock Titan, Ocugen’s SEC filings are updated in near real time from the EDGAR system. AI-powered tools summarize lengthy documents, highlight key sections on clinical programs, licensing terms, capital raises, and governance matters, and make it easier to locate items such as quarterly results, material agreements, and other disclosures relevant to OCGN stock.
Ocugen, Inc. is asking stockholders to vote at its June 11, 2026 virtual annual meeting on four items: electing two Class III directors, ratifying PwC as auditor for 2026, approving executive pay on an advisory basis, and choosing the preferred frequency for future say‑on‑pay votes.
The proxy also highlights major 2025 progress in Ocugen’s modifier gene therapy pipeline, including completion of enrollment in the 140‑patient Phase 3 OCU400 liMeliGhT trial for retinitis pigmentosa, positive Phase 2 OCU410 data in geographic atrophy, and rapid enrollment in the Phase 2/3 GARDian3 trial of OCU410ST for Stargardt disease. Ocugen reports a strong balance sheet supported by a $22.5 million underwritten offering in January 2026 and $15 million from warrant exercises, and details a heavily performance‑based executive compensation program tied to clinical, financial, and talent objectives.
Ocugen, Inc. files an amended preliminary proxy statement for its virtual Annual Meeting on June 11, 2026, updating Proposal 5 to set the reverse stock split range at not less than 1-for-2 and not greater than 1-for-8 (final ratio determined by the Board). The Proxy Statement aussi recaps 2025 program and corporate progress, including completion of enrollment for the OCU400 Phase 3 liMeliGhT trial (140 patients randomized 2:1), topline Phase 3 data expected in Q1 2027, positive Phase 2 OCU410 results (optimal dose: 31% lesion growth reduction, 27% ellipsoid zone preservation, 55% of treated patients ≥30% lesion reduction), and completion of dosing in the GARDian3 Phase 2/3 study (63 participants). The company reports financing activity: $22.5M gross from a January 2026 registered direct offering and an additional $15M gross from exercise of warrants for 10M shares, with proceeds projected to extend cash runway into Q1 2027.
The Proxy Statement also presents governance items: election of two Class III directors (Kirsten Castillo and Satish Chandran), ratification of PwC as independent auditor, advisory votes on executive compensation, and adjournment authority to solicit additional proxies if needed. It describes Board composition (six directors, five independent), committee memberships, director and executive compensation practices, related-party and indemnification arrangements, and certain audit fees for PwC and prior auditor Ernst & Young.
Ocugen, Inc. files a definitive proxy for its virtual Annual Meeting on June 11, 2026 and reviews 2025 progress across clinical, business development, financing, and governance fronts. The company completed enrollment in the Phase 3 liMeliGhT trial for OCU400 with 140 patients (2:1 randomized) and targets topline data in Q1 2027. OCU400 is positioned as a modifier gene therapy intended to address broad retinitis pigmentosa mutations; Ocugen executed a regional license for Korea with Kwangdong Pharmaceutical.
OCU410 reported Phase 2 results showing a 31% statistically significant reduction in lesion growth (optimal dose), 27% ellipsoid zone preservation, and 55% of treated patients with ≥30% lesion reduction. A planned pivotal Phase 3 cohort may enroll up to 300 subjects. The GARDian3 Phase 2/3 trial for OCU410ST enrolled 63 participants. Financing actions included a $22.5M registered direct offering in January 2026 and a $15M warrant exercise (10 million shares), which Ocugen says extends cash runway into Q1 2027. Leadership additions include a new CFO and senior commercial and operations hires. Proxy items include election of two Class III directors and a proposed reverse stock split in the range 1-for-4 to 1-for-8.
Ocugen, Inc. disclosed a Schedule 13G showing that Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander report shared voting and dispositive power over 17,074,584 shares of Common Stock (CUSIP 67577C105), representing 5.2% of the class. The filing is a joint filing and is signed April 13, 2026.
Ocugen, Inc. director Zhang Junge exercised stock options to acquire additional common shares. On April 1, 2026, he exercised options covering 194,134 shares of common stock at exercise prices of $0.51, $0.46, and $1.42 per share. Following these exercises, he directly owns 1,359,316 common shares. The options had previously vested and become exercisable between January 2020 and June 2025.
Ocugen Inc common stock ownership filing shows The Vanguard Group reports zero beneficial ownership and 0% of the class. The filing explains an internal realignment of Vanguard effective January 12, 1998 that led certain subsidiaries to report separately. The form is signed by Ashley Grim on 03/27/2026.
Ocugen, Inc. furnished an investor presentation outlining progress in its gene therapy pipeline for blinding retinal diseases. The company is targeting three biologics license applications over three years for retinitis pigmentosa, Stargardt disease, and geographic atrophy.
OCU400 for retinitis pigmentosa is in Phase 3 with enrollment completed; Phase 1/2 data showed durable visual function gains over three years and no related severe adverse events, with 88% of treated evaluable subjects showing improvement or preservation versus untreated eyes. OCU410ST for Stargardt disease has initiated a pivotal Phase 2/3 trial after Phase 1 data showed atrophic lesion growth 54% slower and visual function stabilized or improved in all treated eyes.
OCU410 for geographic atrophy delivered positive preliminary 12‑month Phase 2 results, including a 31% reduction in lesion size and 27% slower ellipsoid zone loss at the medium dose compared with controls, with no serious or special-interest adverse events deemed related to OCU410. Ocugen plans to start a global Phase 3 GA trial and progress rolling BLA submissions as key upcoming milestones.
Ocugen, Inc. reported positive 12‑month topline Phase 2 ArMaDa data for OCU410, its modifier gene therapy for geographic atrophy secondary to dry age‑related macular degeneration. The optimal medium dose showed a 31% reduction in GA lesion growth versus control at 12 months and a 27% slower loss of the ellipsoid zone, a structural marker linked to visual function. Across treated patients there were no OCU410‑related serious adverse events or adverse events of special interest, supporting a favorable safety and tolerability profile. Based on these results, Ocugen plans to initiate a global Phase 3 registrational trial of OCU410 with up to 300 subjects in the third quarter of 2026, as part of its broader goal of three biologics license applications in three years.
Ocugen, Inc. reports that an institutional investor partially exercised previously issued warrants and purchased 10,000,000 shares of common stock on March 12, 2026. This warrant exercise generated gross proceeds of $15.0 million for Ocugen. The company states that, based on this cash infusion, it now anticipates its cash runway will extend into the first quarter of 2027, supporting ongoing operations and development plans.